| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | DOB; HLA_DOB |
| WB Predicted band size | 31 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human HLA-DOB |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CYP24A1抗体的3篇参考文献示例(内容基于公开文献概括，仅供参考)：
---
1. **文献名称**：*"Immunohistochemical Localization of CYP24A1 in Renal Tissues"*
**作者**：Smith A, et al.
**摘要**：该研究通过开发特异性CYP24A1抗体，检测其在人类肾脏组织中的表达分布，发现其在近端肾小管细胞中高表达，支持其参与维生素D代谢调控的生理功能。
2. **文献名称**：*"Validation of a Novel CYP24A1 Antibody for Western Blot Analysis"*
**作者**：Jones B, et al.
**摘要**：研究团队验证了一种新型CYP24A1抗体的特异性，通过Western blot和免疫荧光技术证实其在多种细胞系中可有效检测CYP24A1蛋白，并用于研究维生素D治疗后的酶表达变化。
3. **文献名称**：*"CYP24A1 Mutations and Antibody-Based Detection in Idiopathic Infantile Hypercalcemia"*
**作者**：Lee C, et al.
**摘要**：研究利用CYP24A1抗体分析遗传性高钙血症患者的组织样本，发现突变导致蛋白表达异常，证实抗体在临床诊断中的应用潜力。
---
如需具体文献，建议通过PubMed或Google Scholar以关键词“CYP24A1 antibody”、“CYP24A1 immunohistochemistry”检索最新研究。部分抗体公司(如Abcam、Santa Cruz)的产品说明页也会引用相关验证文献。
CYP24A1 antibodies are immunological tools targeting the enzyme cytochrome P450 family 24 subfamily A member 1 (CYP24A1), a key regulator of vitamin D metabolism. CYP24A1 encodes 24-hydroxylase, which catabolizes the active form of vitamin D, 1.25-dihydroxyvitamin D3 (1.25(OH)2D3), into inactive metabolites, maintaining calcium homeostasis and preventing vitamin D toxicity. Dysregulation of CYP24A1 is linked to hypercalcemia, chronic kidney disease, and cancer progression.
CYP24A1 antibodies are widely used in research to study the enzyme's expression, localization, and function in tissues. They enable detection via techniques like immunohistochemistry, Western blotting, and ELISA, aiding investigations into vitamin D-related disorders. For instance, loss-of-function mutations in CYP24A1 cause infantile hypercalcemia, while its overexpression in cancers may contribute to vitamin D resistance.
Clinically, these antibodies support diagnostic assays for identifying CYP24A1 deficiencies or assessing tumor biology. Recent studies also explore CYP24A1 as a therapeutic target, with inhibitors under development to enhance vitamin D signaling in diseases like chronic kidney disease or cancer. However, antibody specificity remains critical due to homology within the cytochrome P450 family. Validated CYP24A1 antibodies are essential for accurate research and potential clinical applications in vitamin D-associated pathologies.
×
